CStone Pharmaceuticals (2616.HK) Earnings Analysis
CStone Pharmaceuticals (2616.HK) next reports earnings on 2026-08-20, consensus EPS -0.21938 HKD. Last quarter (2026-03-26) it missed with EPS -0.13355 HKD vs -0.05564 HKD est (-140%). It has beaten estimates in 1/3 recent quarters (33%). Trailing P/E -20.06.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does 2616.HK next report earnings?
| Next earnings date | 2026-08-20 |
|---|---|
| Consensus EPS estimate | -0.21938 HKD |
| Revenue estimate | 0.16B |
2616.HK earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-03-26 | -0.13355 HKD | -0.05564 HKD | -140% | Miss |
| 2025-08-14 | -0.11247 HKD | -0.10958 HKD | -2.6% | Miss |
| 2024-12-31 | -0.08907 HKD | n/a | n/a | n/a |
| 2024-08-23 | 0.01074 HKD | -0.10744 HKD | +110% | Beat |
Beat rate: 1/3 (33%) over reported quarters with consensus data.
2616.HK valuation and analyst view
| Trailing P/E | -20.06 |
|---|---|
| Trailing EPS | -0.20641 HKD |
| Price / book | 9.99 |
| Dividend yield | 0.00% |
| Market cap | 7.58B |
Limited or no published sell-side analyst coverage for this symbol.
Related research pages
Frequently asked questions
When is CStone Pharmaceuticals (2616.HK)'s next earnings date?
CStone Pharmaceuticals is next scheduled to report on 2026-08-20, with a consensus EPS estimate of -0.21938 HKD and revenue estimate of 0.16B.
Did 2616.HK beat earnings last quarter?
In its 2026-03-26 report, 2616.HK posted EPS of -0.13355 HKD versus a -0.05564 HKD estimate — a miss of 140%.
What is 2616.HK's earnings track record?
Over the last 3 reported quarters with consensus data, 2616.HK beat estimates 1 times (33%).
What is 2616.HK's current P/E ratio and EPS?
2616.HK trades at a trailing P/E of -20.06 on trailing EPS of -0.20641176360523314 HKD.
What do analysts rate 2616.HK?
2616.HK has limited or no published sell-side analyst coverage in our dataset, so no consensus rating is shown. Fundamentals and earnings history above are sourced from company filings via FMP.